Seeking Alpha

Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring...

Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring Committee, it's terminating its Phase 3 study of its pancreatic cancer drug Ganitumab. After reviewing the pre-planned interim analysis, the committee concluded that the drug was unlikely to demonstrate a statistically significant improvement towards the primary endpoint of overall survival. Shares -0.9% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|